# Efficacy, Safety, and Tolerability, of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis

> **NCT05152173** · PHASE2 · COMPLETED · sponsor: **Endo Pharmaceuticals** · enrollment: 176 (actual)

## Conditions studied

- Plantar Fibromatosis

## Interventions

- **BIOLOGICAL:** EN3835
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05152173
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-29
- **Primary completion:** 2023-01-10
- **Final completion:** 2023-01-10
- **Target enrollment:** 176 (ACTUAL)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05152173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05152173, "Efficacy, Safety, and Tolerability, of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05152173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*